
    
      This is a randomized, double blind, placebo controlled study of a maximum of 24 subjects with
      constipation predominant irritable bowel syndrome (IBS-C). Sixteen subjects will receive
      active treatment and 8 subjects will receive matching placebo. There will be a 21-day
      screening phase before 1st study drug administration on Day 1.
    
  